Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 15/20 | 1.00 |
| ▸ | NR1H3 | Q13133 | 10/20 | 0.67 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3492016 | 0.89 | NR1H2 (1.00) | NR1H2NR1H3 | |
| SCHEMBL3491581 | 0.86 | NR1H2 (1.00) | NR1H2NR1H3CYP3A4 | |
| SCHEMBL3489919 | 0.84 | NR1H2 (0.91) | NR1H2NR1H3 | |
| SCHEMBL3491902 | 0.83 | NR1H2 (0.89) | NR1H2NR1H3 | |
| SCHEMBL2319056 | 0.83 | NR1H2 (0.70) | NR1H2NR1H3 | |
| SCHEMBL3490740 | 0.82 | NR1H2 (0.83) | NR1H2NR1H3 | |
| SCHEMBL3490508 | 0.82 | NR1H2 (0.92) | NR1H2NR1H3CYP3A4 | |
| SCHEMBL3492028 | 0.82 | NR1H2 (0.83) | NR1H2NR1H3 | |
| SCHEMBL3490410 | 0.80 | NR1H2 (1.00) | NR1H2NR1H3 | |
| SCHEMBL2358477 | 0.80 | NR1H2 (0.67) | NR1H2NR1H3CYP1A2CYP3A4CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2010054229-A1 | QUINOXALINE-BASED LXR MODULATORS | WYETH LLC (US) | 2010-05-14 | — | — | WO | disclosed |
| US-20100120778-A1 | QUINOXALINE-BASED LXR MODULATORS | WYETH (US) | 2010-05-13 | — | — | US | disclosed |
| US-20100120778-A1 | QUINOXALINE-BASED LXR MODULATORS | WYETH (US) | 2010-05-13 | — | — | US | disclosed |
| US-20100120778-A1 | QUINOXALINE-BASED LXR MODULATORS | WYETH (US) | 2010-05-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100120778-A1 | QUINOXALINE-BASED LXR MODULATORS | NR1H2, NR1H3, NR1H4 | NR1H2 1/4885NR1H3 2/4885CYP1A2 145/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.